Innate Pharma (IPH) Corporate presentation summary

Strategic focus and portfolio overview

• Focused on high-value oncology assets with in-house antibody and ADC expertise.

• Portfolio includes late-stage partnered assets and a proprietary ADC pipeline.

• Organization reshaped for agile execution and impact.

Key clinical assets and partnerships

• Lacutamab (anti-KIR3DL2 mAb) partnered with Sobi, advancing to Phase 3 TELLOMAK-3 in CTCL, targeting accelerated approval in Sézary syndrome.

• Monalizumab (anti-NKG2A mAb) co-developed with AstraZeneca, with Phase 3 PACIFIC-9 in NSCLC; Phase 2 data showed prolonged PFS with combination therapy.

• IPH4502 (Nectin-4 ADC) wholly owned, with Phase 1 dose escalation completed and preliminary anti-tumor activity observed in multiple solid tumors.

Clinical data and market opportunity

• Lacutamab Phase 2 showed durable responses and favorable safety in CTCL, supporting accelerated approval plans.

• High unmet need in CTCL, with lacutamab positioned for significant market expansion and peak year sales potential over $500M.

• IPH4502 demonstrated activity in preclinical and early clinical settings, addressing resistance and heterogeneity in solid tumors.